Residual disease

Questions discussed in this category

How would you treat a patient with TNBC with a residual strongly PR+, ER- breast mass on mastectomy after neoadjuvant KEYNOTE 522 based chemoimmunotherapy?

Would you consider using endocrine therapy, pembrolizumab, capecitabine, or CDK 4/6 inhibitor?

1 Answer available

Based on data from CREATE-X/JBCRG-04, would you consider adjuvant capecitabine in breast cancer patients treated with neoadjuvant chemotherapy who do not achieve a pCR?

Masuda et al. NEJM 2017 If so, how do you sequence it with adjuvant radiotherapy?

2 Answers available

What is your approach to patients with locally advanced triple negative breast cancer with residual disease at the time of surgery?

Are you using post-neoadjuvant Xeloda based on preliminary data from the CREATE-X trial? Does BRCA mutation influence your decision?

1 Answer available

Papers discussed in this category

N. Engl. J. Med.,

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

ESMO Open, 2016-01-01

Highlights from the San Antonio Breast Cancer Symposium 2015.

N. Engl. J. Med.,

Pembrolizumab for Early Triple-Negative Breast Cancer.

Related Topics